EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

High prevalence of cefiderocol resistance in carbapenem-resistant Escherichia coli: A warning from multicenter clinical data in China

Ye Lu, Peng Lan, Wenzeng Xu, Lina Chen, Junxin Zhou, Qianyi Chen, Ying Cui, Yan Jiang, Yunsong Yu, Jiancang Zhou

Journal of Infection · 2025

DOI: 10.1016/j.jinf.2025.106563 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Infection, 2025. Verfasst von Ye Lu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Cephalosporins, Escherichia coli Infections, Escherichia coli. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer, National Key Research and Development Program of China, Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: This study aimed to evaluate the in vitro efficacy of cefiderocol and other agents against carbapenem-resistant Escherichia coli (CREC) clinical isolates in China and to elucidate the genetic mechanisms underlying cefiderocol resistance. METHODS: A total of 638 non-duplicated CREC isolates were collected from 27 tertiary hospitals across China. Minimum inhibitory concentrations (MICs) of antimicrobial agents were determined by using agar dilution and broth microdilution methods. Whole-genome sequencing and bioinformatics analyses were conducted to identify resistance genes and mutations. Gene knockout, complementation, and CRISPR-Cas9 editing were used to validate resistance mechanisms. RESULTS: In vitro activity testing was conducted on 16 antimicrobial agents against all CREC isolates. Among these agents, tigecycline exhibited the highest antibacterial activity (100%), followed by polymyxin B (95.9%). However, only 82.5% of the strains were susceptible to cefiderocol, and its MIC90 reached as high as >128 mg/L. Among 99 cefiderocol-resistant Escherichia coli isolates, ST167 was the most prevalent. Over 90% of cefiderocol-resistant isolates harbored mutations or disruptions in cirA, in which functional validation confirmed that cirA inactivation, combined with NDM expression, significantly increased cefiderocol MICs. Additional resistance mechanisms included blaCMY-2 overexpression and ftsI mutations. CONCLUSIONS: Cefiderocol shows promising activity against most CREC isolates in China; however, a notable proportion of resistance is emerging, particularly among NDM-producing clones with CirA loss.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsCephalosporinsEscherichia coli InfectionsEscherichia coliCarbapenem-Resistant EnterobacteriaceaeCarbapenemsDrug Resistance, BacterialChinaMicrobial Sensitivity TestsHumansCefiderocolPrevalenceWhole Genome SequencingMutationEscherichia coli Proteins

Stichwörter der Autor:innen

Carbapenem-Resistant Escherichia coliCefiderocolCirANDMResistance Mechanism

Substanzen

Anti-Bacterial AgentsCephalosporinsCefiderocolCarbapenemsEscherichia coli Proteins

Autor:innen und Institutionen

  • Department of Critical Care Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Clinical Nutrition, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, Zhejiang, China.
  • Department of Critical Care Medicine, the Fourth Affiliated Hospital Zhejiang University School of Medicine, Yiwu, China.
  • Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: yvys119@zju.edu.cn.
  • Department of Critical Care Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: jiancangzhou@zju.edu.cn.

Förderung

  • Pfizer
  • National Key Research and Development Program of China
  • Natural Science Foundation of Zhejiang Province
  • National Natural Science Foundation of China

Zitieren

APA

Lu, Y., Lan, P., Xu, W., Chen, L., Zhou, J., Chen, Q., Cui, Y., Jiang, Y., Yu, Y., & Zhou, J. (2025). High prevalence of cefiderocol resistance in carbapenem-resistant Escherichia coli: A warning from multicenter clinical data in China. Journal of Infection. https://doi.org/10.1016/j.jinf.2025.106563

Vancouver

Lu Y, Lan P, Xu W, Chen L, Zhou J, Chen Q, et al. High prevalence of cefiderocol resistance in carbapenem-resistant Escherichia coli: A warning from multicenter clinical data in China. Journal of Infection. 2025. doi:10.1016/j.jinf.2025.106563

BibTeX
@article{Lu2025,
  author = {Lu, Ye and Lan, Peng and Xu, Wenzeng and Chen, Lina and Zhou, Junxin and Chen, Qianyi and Cui, Ying and Jiang, Yan and Yu, Yunsong and Zhou, Jiancang},
  title = {High prevalence of cefiderocol resistance in carbapenem-resistant Escherichia coli: A warning from multicenter clinical data in China},
  journal = {Journal of Infection},
  year = {2025},
  doi = {10.1016/j.jinf.2025.106563}
}
Kostenlos starten →